Use of ENTPD3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
Summary
The USPTO granted patent US12594306B2 to the Regents of the University of Colorado on April 7, 2026. The patent covers methods and compositions for identifying, sorting, and separating stem cell-derived pancreatic beta cells using the cell surface protein ENTPD3 (CD39L3) for diabetes treatment applications. The patent includes 13 claims and has a filing date of March 25, 2022.
What changed
The USPTO issued patent US12594306B2 to the University of Colorado covering methods for identifying, isolating, and enhancing mature stem cell-derived insulin-producing cells using ENTPD3 (CD39L3) for cell-based therapies targeting diabetes, including Type-1 diabetes. The patent discloses compositions and systems for live-sorting heterogeneous populations of stem cell-derived pancreatic beta cells into functionally homogeneous populations.\n\nResearch institutions, biotechnology companies, and pharmaceutical companies developing stem cell-based diabetes treatments should monitor this IP landscape. The patent may affect freedom-to-operate for competing approaches in cell therapy development targeting beta cell replacement or diabetes treatment. Licensing discussions may be warranted for parties developing similar cell sorting or identification methodologies.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use of ENTPD3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
Grant US12594306B2 Kind: B2 Apr 07, 2026
Assignee
The Regents of the University of Colorado, A Body Corporate
Inventors
Holger A. Russ, Fiona Docherty
Abstract
Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.
CPC Classifications
A61K 35/39
Filing Date
2022-03-25
Application No.
17704429
Claims
13
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.